|
Name |
Cholan-16-one, 23-methyl-, (5alpha,20xi)-
|
| Molecular Formula | C25H42O | |
| IUPAC Name* |
(5R,8R,9S,10S,13S,14S,17R)-10,13-dimethyl-17-[(2R)-4-methylpentan-2-yl]-1,2,3,4,5,6,7,8,9,11,12,14,15,17-tetradecahydrocyclopenta[a]phenanthren-16-one
|
|
| SMILES |
C[C@H](CC(C)C)[C@H]1C(=O)C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(CCCC4)C)C
|
|
| InChI |
InChI=1S/C25H42O/c1-16(2)14-17(3)23-22(26)15-21-19-10-9-18-8-6-7-12-24(18,4)20(19)11-13-25(21,23)5/h16-21,23H,6-15H2,1-5H3/t17-,18-,19-,20+,21+,23+,24+,25+/m1/s1
|
|
| InChIKey |
RVDADQFBPPLLTP-IQGOHZNHSA-N
|
|
| Synonyms |
Cholan-16-one, 23-methyl-, (5.alpha.,20.xi.)-
|
|
| CAS | NA | |
| PubChem CID | 91743343 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 358.6 | ALogp: | 8.4 |
| HBD: | 0 | HBA: | 1 |
| Rotatable Bonds: | 3 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 17.1 | Aromatic Rings: | 4 |
| Heavy Atoms: | 26 | QED Weighted: | 0.54 |
| Caco-2 Permeability: | -4.733 | MDCK Permeability: | 0.00001050 |
| Pgp-inhibitor: | 0.982 | Pgp-substrate: | 0.002 |
| Human Intestinal Absorption (HIA): | 0.002 | 20% Bioavailability (F20%): | 0.996 |
| 30% Bioavailability (F30%): | 0.992 |
| Blood-Brain-Barrier Penetration (BBB): | 0.501 | Plasma Protein Binding (PPB): | 96.67% |
| Volume Distribution (VD): | 1.396 | Fu: | 1.65% |
| CYP1A2-inhibitor: | 0.149 | CYP1A2-substrate: | 0.318 |
| CYP2C19-inhibitor: | 0.253 | CYP2C19-substrate: | 0.908 |
| CYP2C9-inhibitor: | 0.352 | CYP2C9-substrate: | 0.128 |
| CYP2D6-inhibitor: | 0.042 | CYP2D6-substrate: | 0.099 |
| CYP3A4-inhibitor: | 0.629 | CYP3A4-substrate: | 0.386 |
| Clearance (CL): | 19.366 | Half-life (T1/2): | 0.072 |
| hERG Blockers: | 0.762 | Human Hepatotoxicity (H-HT): | 0.229 |
| Drug-inuced Liver Injury (DILI): | 0.866 | AMES Toxicity: | 0.013 |
| Rat Oral Acute Toxicity: | 0.585 | Maximum Recommended Daily Dose: | 0.045 |
| Skin Sensitization: | 0.94 | Carcinogencity: | 0.13 |
| Eye Corrosion: | 0.954 | Eye Irritation: | 0.675 |
| Respiratory Toxicity: | 0.971 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC002305 | ![]() |
0.432 | D04DJN | ![]() |
0.489 | ||
| ENC000125 | ![]() |
0.429 | D09NNA | ![]() |
0.440 | ||
| ENC003337 | ![]() |
0.427 | D00VZZ | ![]() |
0.432 | ||
| ENC001475 | ![]() |
0.411 | D0U3GL | ![]() |
0.415 | ||
| ENC001764 | ![]() |
0.409 | D0Y7LD | ![]() |
0.396 | ||
| ENC002882 | ![]() |
0.409 | D0Q6NZ | ![]() |
0.394 | ||
| ENC005239 | ![]() |
0.409 | D06XMU | ![]() |
0.365 | ||
| ENC000961 | ![]() |
0.407 | D07BSQ | ![]() |
0.360 | ||
| ENC003458 | ![]() |
0.396 | D0B4RU | ![]() |
0.360 | ||
| ENC001008 | ![]() |
0.396 | D08QKJ | ![]() |
0.359 | ||